Acceleron Pharma (XLRN) PT Raised to $173 at Cowen

February 18, 2021 6:20 AM EST
Get Alerts XLRN Hot Sheet
Price: $124.11 +0.84%

Rating Summary:
    17 Buy, 4 Hold, 0 Sell

Rating Trend: Up Up

Today's Overall Ratings:
    Up: 12 | Down: 16 | New: 51
Trade Now! 
Join SI Premium – FREE

Get instant alerts when news breaks on your stocks. Claim your 1-week free trial to StreetInsider Premium here.

Cowen analyst Yaron Werber raised the price target on Acceleron Pharma (NASDAQ: XLRN) to $173.00 (from $137.00) while maintaining an Outperform rating.

The analyst commented, "We are increasing our PT to $173 (+$36) based on higher peak penetration estimates for sotatercept as the first disease-modifying therapy in PAH. We believe sotatercept should drive the stock high over the long term with peak sales reaching $3-$4B, while at the same time the strong Reblozyl franchise grows toward its own $4B+ opportunity."

Serious News for Serious Traders! Try Premium Free!

You May Also Be Interested In

Related Categories

Analyst Comments, Analyst PT Change

Related Entities

Cowen & Co